Author
Corona Remedies IPO closes on December 10, 2025. The IPO comprises an entirely Offer for Sale (OFS) of ₹655.37 crore, with no fresh issue component. The price band for the issue is fixed at ₹1,008–₹1,062 per share.
The basis of allotment is expected to be finalized on December 11, 2025, while refunds and demat credit are scheduled for December 12, 2025. The shares are tentatively set to list on December 15, 2025 on both BSE and NSE.
Corona Remedies Ltd is a branded pharmaceutical formulations company focused on the Indian market, with a presence across multiple chronic and acute therapeutic segments.
Registrar: Bigshare Services Pvt. Ltd.
| Investor Category | Subscription (Times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 293.8× |
| HNIs | 28.30× |
| Retail Individual Investors (RII) | 30.29× |
| Employees | 15.56× |
| Total | 144.49× |
Corona Remedies Ltd is a branded pharmaceutical company operating in the Indian pharmaceutical market, with a portfolio spanning women’s healthcare, cardio-diabeto, pain management, urology, anti-infectives, nutraceuticals, orthopedics, and pediatrics.
In FY25, the company reported revenues of approximately ₹1,200 crore, while net profit rose sharply to around ₹149 crore, reflecting strong earnings growth and margin expansion.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with India’s First Drug-Free Device 'Pepair' at ₹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with India’s First Affordable Drug-Free Device ‘PepairTM’ at ₹990